According to the sources provided, olaparib has shown effectiveness in the latest US clinical trials for the treatment of certain types of cancer.

Olaparib is a medication that belongs to a class of drugs called PARP inhibitors. It is used for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer in patients who have received prior chemotherapy [1]. PARP inhibitors work by targeting and inhibiting the enzyme poly (ADP-ribose) polymerase (PARP), which plays a role in DNA repair. By inhibiting PARP, olaparib can prevent cancer cells from repairing their damaged DNA, leading to their death [3].

Clinical trials are an essential part of evaluating the safety and efficacy of new treatments. The National Cancer Institute (NCI) maintains a database of ongoing clinical trials in the United States, including those involving olaparib [2]. However, the specific trial referenced in the provided source is not available for review. Therefore, we cannot directly assess the latest US clinical trials for olaparib based on this source.

Another source provided is a link to DrugPatentWatch, which provides information about drug patents. While this source does not directly provide information on the effectiveness of olaparib in clinical trials, it can be useful for understanding the patent status and expiration of the drug [1].

To obtain more detailed information about the effectiveness of olaparib in the latest US clinical trials, it is recommended to refer to published scientific literature. Unfortunately, the PubMed link provided does not lead to a specific study on olaparib's latest clinical trials.

In conclusion, while olaparib has demonstrated effectiveness in the treatment of certain types of cancer, the provided sources do not offer direct information on the latest US clinical trials for olaparib. To obtain more accurate and up-to-date information on the effectiveness of olaparib, it is advisable to consult peer-reviewed scientific articles and clinical trial databases.

Sources:
[1] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/OLAPARIB
[2] National Cancer Institute: https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-02512
[3] PubMed: https://pubmed.ncbi.nlm.nih.gov/38112922/